Afatinib versus osimertinib for non–small cell lung cancer with uncommon epidermal growth factor receptor mutations: Real-world outcomes (HOT-Next001/HOT2501).
Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo et autres
8605 Background: Non–small cell lung cancers (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations exhibit considerable biological and clinical heterogeneity. Consequently, the optimal first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) and the role of subsequent immune checkpoint inhibitor (ICI)–based regimens remain uncertain. …
jp (code pays fourni par la source)
0 citations
Journal of Clinical Oncology